Canopy Growth Corp (CGC) Stock Price, Quote & News

Company Profile

Canopy Growth Corporation, together with its subsidiaries, engages in the production, distribution, and sale of cannabis, hemp, and cannabis-related products in Canada, Germany, and Australia. It operates through four segments: Canada Cannabis, International Markets Cannabis, and Storz & Bickel, and This Works. The company offers dried flower and pre-rolled joints; extracts and concentrates, such as softgel capsules; cannabis edibles, including gummies; cannabis vapes; and oils, beverages, conce...

Industry: Drug Manufacturers - Specialty & Generic

Sector: Healthcare

Phone: 855 558 9333

Website: www.canopygrowth.com

Address:

1 Hershey Drive, Smiths Falls, Canada

StonkCapital Jan. 25 at 4:33 PM

$TLRY $MSOS $ACB $CGC Thoughtful, informative commentary is appreciated whether it's coming from a bear or bull. However, the Canadian companies are still growing in an environment that's becoming more favorable every year. They have lots of international deals and some trade around 1x annual revenue compared to tech stocks at 100x. Investors want to find value and that's becoming hard to do in this market.

0 · Reply

Winston_ Jan. 25 at 3:34 PM

$TLRY $MSOS $ACB $CGC AI Overview 2. Disconnect Between Hype and Business Reality No Immediate U.S. Cannabis Revenue: Although rescheduling helps U.S.-based multi-state operators (MSOs) by reducing tax burdens (280e), it provides minimal immediate, tangible benefits to Canadian-based companies like Tilray that lack established, direct-to-consumer THC operations in the U.S.. In summary, the "pump and dump" narrative surrounding Tilray and rescheduling stems from the stock being used as a high-liquidity, high-volatility vehicle to trade speculation about U.S. policy, rather than a reflection of its underlying business strength. Beware of the unconscionable and rabidly optimistic pumptards who partner with shorts to shear sheep. Just the facts.

1 · Reply

SlothMan2026 Jan. 25 at 2:57 PM

Let’s get 🪨 stoned 🪨 “𝐃𝐚𝐫𝐤𝐞𝐬𝐭 𝐁𝐞𝐟𝐨𝐫𝐞 𝐭𝐡𝐞 𝐃𝐚𝐰𝐧: 𝐂𝐀𝐏𝐒...𝐄𝐱𝐩𝐚𝐧𝐝𝐬 𝐈𝐭𝐬 𝐅𝐨𝐨𝐭𝐩𝐫𝐢𝐧𝐭 𝐈𝐧𝐭𝐨 𝐒𝐨𝐮𝐭𝐡𝐞𝐚𝐬𝐭. 𝐖𝐞 𝐀𝐟𝐟𝐢𝐫𝐦 𝐁𝐔𝐘, $6 𝐏𝐓” $CGC crew, CAPS is a 𝐬𝐥𝐞𝐞𝐩𝐢𝐧𝐠 𝐠𝐢𝐚𝐧𝐭. The float’s locking up & they’re making moves, 𝐛𝐮𝐢𝐥𝐝𝐢𝐧𝐠 𝐨𝐮𝐭 𝐚 𝐖𝐌𝐓/𝐀𝐌𝐙𝐍-𝐭𝐲𝐩𝐞 𝐩𝐥𝐚𝐭𝐟𝐨𝐫𝐦 in a fragmented market. Stone veneer’s resilient in a recession & beautiful when the market blossoms. 𝘛𝘩𝘪𝘴 𝘪𝘴 𝘵𝘩𝘦 𝘤𝘩𝘦𝘢𝘱𝘦𝘴𝘵 𝘐𝘗𝘖 𝘵𝘩𝘢𝘵 𝘺𝘰𝘶’𝘭𝘭 𝘦𝘷𝘦𝘳 𝘧𝘪𝘯𝘥. Insiders hold 3.7𝐌 𝐬𝐡𝐚𝐫𝐞𝐬, our board holds >1𝐌 𝐬𝐡𝐚𝐫𝐞𝐬, & institutional holdings are trickling in QoQ. If they 𝐥𝐢𝐤𝐞𝐝 it >$1, they’re 𝐥𝐨𝐯𝐢𝐧𝐠 it at these prices. 𝘉𝘶𝘺𝘪𝘯𝘨 𝘖𝘗𝘌𝘕 𝘪𝘯 𝘵𝘩𝘦 $.60𝘴 & $.70𝘴 𝘸𝘢𝘴 𝘤𝘳𝘢𝘻𝘺 𝘶𝘯𝘵𝘪𝘭 𝘪𝘵 𝘸𝘢𝘴𝘯’𝘵... 𝐓𝐡𝐞 𝐜𝐚𝐭𝐚𝐥𝐲𝐬𝐭𝐬 𝐚𝐫𝐞 𝐭𝐡𝐞𝐫𝐞; it just doesn’t have 👁️👁️ https://drive.google.com/file/d/1KJNrdkTTJBX2dqwBlRSR6dgyTy6YWybm/view?usp=sharing

0 · Reply

DipNrip75 Jan. 25 at 2:45 PM

$TLRY @Winston_ @FuggNMoney @Jokerit ALL cannabis companies will benefit from 280E, that’s a value which pertains to long term stability and growth by improving speed to profitability. The immediate WINNING tickers whether it be $TLRY $MSOS $ACB $CGC $SNDL etc…will be from the fastest movers in the medical space, this is where all the development and selling opportunities will come from with subsidies and institutional support to capture the most market share as possible before their competitors do. With the launch of Tilray Medical on DAY 1 of S3 announcement in December and last weeks news release regarding Tilray Italia, I can’t help but be overly confident that Tilly will collect an MVP and possibly 🥇in a couple/few years. Regardless, 🍀 to all the Cannabis 🐂🐂🐂, you all deserve a win considering the beating the sector has taken in the last 5 years. ❤️ your Cannabis Fam Everyone!!

0 · Reply

Jokerit Jan. 25 at 2:11 PM

$SNDL $TLRY $MSOS $ACB $CGC Just the facts LOL, No KID you are a moron. MSOS are the ones working with alcohol and tobacco companies to lobby against hemp industry with mitch because they know they will lose big, TLRY is already incorporated in the USA... or did you not realize they have been an AMERICAN COMPANY ALL ALONG... but DBA Canadian. They have all the distribution they needin USA ad are ready go. YOU MORON. Just The Facts

2 · Reply

akroller Jan. 25 at 1:46 PM

$CGC $TLRY God's gift to god.

0 · Reply

Winston_ Jan. 25 at 11:59 AM

$TLRY $MSOS $ACB $CGC @FuggNMoney are you woefully ignorant or intentionally trying to deceive people? AI Overview U.S. Multi-State Operators (MSOs) are poised to benefit significantly more than Tilray from cannabis rescheduling to Schedule III primarily because MSOs directly operate in the U.S. cannabis market, allowing them to immediately eliminate the punitive tax burdens of Section 280E. While Tilray (a Canadian Licensed Producer) has exposure to the U.S. through acquisitions in beverages and hemp, it lacks direct "plant-touching" cannabis operations in the U.S. that would benefit from these tax changes. Just the facts.

1 · Reply

marketfan1 Jan. 25 at 11:51 AM

$TLRY $CGC $ACB Mr prez please take note, your benevolent decisions are being held back, medical marijuana has immense potential for so many types of disease, in palliative care itself it has numerous usage, cancer, immunity are others, there are definitely some vested interests blocking this, please do something Mr. Prez.

0 · Reply